BRPI0517425A - composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto - Google Patents
composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de compostoInfo
- Publication number
- BRPI0517425A BRPI0517425A BRPI0517425-2A BRPI0517425A BRPI0517425A BR PI0517425 A BRPI0517425 A BR PI0517425A BR PI0517425 A BRPI0517425 A BR PI0517425A BR PI0517425 A BRPI0517425 A BR PI0517425A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- enantiomer
- solvate
- diastereomer
- diastereomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
COMPOSTO OU UM SAL, SOLVATO, ENANCIÈMERO, DIASTEREÈMERO OU MISTURA DE DIASTEREÈMEROS DO MESMO, COMPOSIçãO FARMACêUTICA, E, USO DE COMPOSTO. A presente invenção refere-se a um composto de fórmula (I) antagonista de hormónio concentradór de melanina; na qual Ar, L~ 1~, R, q, X, R, R, R~ 4~, e R~ 5~ são como definidos, ou um seu sal, solvato, ou enanciómero farmaceuticamente aceitável útil no tratamento, na prevenção ou na melhoria de sintomas associados com obesidade e doenças relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63711604P | 2004-12-17 | 2004-12-17 | |
PCT/US2005/045864 WO2006066173A2 (en) | 2004-12-17 | 2005-12-16 | Novel mch receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517425A true BRPI0517425A (pt) | 2008-10-07 |
Family
ID=36481254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517425-2A BRPI0517425A (pt) | 2004-12-17 | 2005-12-16 | composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto |
Country Status (16)
Country | Link |
---|---|
US (1) | US7838543B2 (pt) |
EP (1) | EP1828177B1 (pt) |
JP (1) | JP4988591B2 (pt) |
CN (1) | CN101072775A (pt) |
AT (1) | ATE404555T1 (pt) |
AU (1) | AU2005316313B2 (pt) |
BR (1) | BRPI0517425A (pt) |
CA (1) | CA2589678A1 (pt) |
DE (1) | DE602005009021D1 (pt) |
DK (1) | DK1828177T3 (pt) |
ES (1) | ES2312048T3 (pt) |
MX (1) | MX2007007226A (pt) |
PL (1) | PL1828177T3 (pt) |
PT (1) | PT1828177E (pt) |
SI (1) | SI1828177T1 (pt) |
WO (1) | WO2006066173A2 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005290436A1 (en) | 2004-10-01 | 2006-04-13 | Banyu Pharmaceutical Co.,Ltd | 2-arylcarboxamide-nitrogeneous heterocycle compound |
WO2006066174A1 (en) * | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
BRPI0607308A2 (pt) * | 2005-01-25 | 2009-08-25 | Synta Pharmaceuticals Corp | compostos, composições farmacêuticas e usos dos referidos compostos |
US8153813B2 (en) * | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
US20110306597A1 (en) | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
WO2010010435A2 (en) * | 2008-07-22 | 2010-01-28 | Glenmark Pharmaceutical S.A. | Fused oxazole and thiazole derivatives as trpms modulators |
SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
KR20130041177A (ko) | 2010-07-06 | 2013-04-24 | 아스트라제네카 아베 | 치료제 976 |
WO2012007500A2 (de) * | 2010-07-15 | 2012-01-19 | Bayer Cropscience Ag | Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel |
TW201305152A (zh) * | 2010-12-14 | 2013-02-01 | Shionogi & Co | 具有血管內皮脂肪酶抑制活性之苯并噻唑及吖苯并噻唑衍生物 |
UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
DK3094329T3 (en) | 2014-01-13 | 2018-11-19 | Aurigene Discovery Tech Ltd | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAC4 INHIBITORS |
JP6802194B2 (ja) | 2015-06-22 | 2020-12-16 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | Nadphオキシダーゼ4阻害剤 |
AU2016293446A1 (en) * | 2015-07-15 | 2018-02-15 | Aurigene Discovery Technologies Limited | Substituted aza compounds as IRAK-4 inhibitors |
MX2019011158A (es) * | 2017-03-31 | 2019-10-17 | Aurigene Discovery Tech Ltd | Compuestos y composiciones para tratar trastornos hematologicos. |
FI3704108T3 (fi) | 2017-10-31 | 2024-05-23 | Curis Inc | Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon |
CN109485620A (zh) * | 2018-12-26 | 2019-03-19 | 安徽工大化工科技有限公司 | 一种2-甲氧基-6-甲氧基苯并噻唑的制备方法 |
SG11202112226WA (en) * | 2019-05-14 | 2021-12-30 | Metabomed Ltd | Acss2 inhibitors and methods of use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10500960A (ja) | 1994-05-28 | 1998-01-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5ht1d−アンタゴニスト活性を有するアミド誘導体 |
ATE390404T1 (de) | 1997-02-27 | 2008-04-15 | Takeda Pharmaceutical | Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta |
CA2386474A1 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
AU2001236698A1 (en) | 2000-02-07 | 2001-08-14 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
CA2407149C (en) * | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
AU2001256733A1 (en) * | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
EP1332131A2 (en) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
DE10139126A1 (de) * | 2001-08-09 | 2003-02-20 | Ciba Sc Pfersee Gmbh | Zusammensetzungen aus Polysiloxanen, Fluorpolymeren und Extendern |
DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP2005518371A (ja) * | 2001-12-10 | 2005-06-23 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
US7541477B2 (en) * | 2002-07-30 | 2009-06-02 | Banyu Pharmaceutical Co., Ltd. | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
JP2006516254A (ja) * | 2003-01-06 | 2006-06-29 | イーライ・リリー・アンド・カンパニー | Pparモジュレータとしての縮合ヘテロ環誘導体 |
WO2006094682A1 (en) * | 2005-03-09 | 2006-09-14 | F. Hoffmann-La Roche Ag | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds |
-
2005
- 2005-12-16 EP EP05854552A patent/EP1828177B1/en not_active Not-in-force
- 2005-12-16 BR BRPI0517425-2A patent/BRPI0517425A/pt not_active IP Right Cessation
- 2005-12-16 AU AU2005316313A patent/AU2005316313B2/en not_active Ceased
- 2005-12-16 US US11/719,576 patent/US7838543B2/en not_active Expired - Fee Related
- 2005-12-16 CA CA002589678A patent/CA2589678A1/en not_active Abandoned
- 2005-12-16 DE DE602005009021T patent/DE602005009021D1/de active Active
- 2005-12-16 JP JP2007546990A patent/JP4988591B2/ja not_active Expired - Fee Related
- 2005-12-16 CN CNA2005800418488A patent/CN101072775A/zh active Pending
- 2005-12-16 AT AT05854552T patent/ATE404555T1/de active
- 2005-12-16 PL PL05854552T patent/PL1828177T3/pl unknown
- 2005-12-16 MX MX2007007226A patent/MX2007007226A/es active IP Right Grant
- 2005-12-16 DK DK05854552T patent/DK1828177T3/da active
- 2005-12-16 PT PT05854552T patent/PT1828177E/pt unknown
- 2005-12-16 SI SI200530456T patent/SI1828177T1/sl unknown
- 2005-12-16 ES ES05854552T patent/ES2312048T3/es active Active
- 2005-12-16 WO PCT/US2005/045864 patent/WO2006066173A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
PT1828177E (pt) | 2008-10-28 |
MX2007007226A (es) | 2007-08-21 |
DE602005009021D1 (de) | 2008-09-25 |
EP1828177A2 (en) | 2007-09-05 |
ES2312048T3 (es) | 2009-02-16 |
CN101072775A (zh) | 2007-11-14 |
JP2008524249A (ja) | 2008-07-10 |
ATE404555T1 (de) | 2008-08-15 |
DK1828177T3 (da) | 2008-11-17 |
EP1828177B1 (en) | 2008-08-13 |
SI1828177T1 (sl) | 2009-02-28 |
AU2005316313A1 (en) | 2006-06-22 |
WO2006066173A3 (en) | 2006-07-27 |
PL1828177T3 (pl) | 2009-01-30 |
US20090170913A1 (en) | 2009-07-02 |
CA2589678A1 (en) | 2006-06-22 |
WO2006066173A2 (en) | 2006-06-22 |
AU2005316313B2 (en) | 2011-09-29 |
US7838543B2 (en) | 2010-11-23 |
JP4988591B2 (ja) | 2012-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517425A (pt) | composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto | |
BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
ATE360631T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
TW200716574A (en) | The preparation and use of compounds as aspartyl protease inhibitors | |
BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
UY30183A1 (es) | Derivados de quinolina | |
WO2007146758A3 (en) | Novel mch receptor antagonists | |
MXPA03005464A (es) | Agentes antivirales. | |
ATE435855T1 (de) | Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor | |
TW200745111A (en) | New compounds | |
TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
DE602004024375D1 (de) | Carboxamidderivate | |
IS2376B (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
SI1735278T1 (sl) | Agenti histamin h receptorja priprava in terapevtska uporaba | |
TW200606164A (en) | New compounds | |
BRPI0411673A (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
TW200800984A (en) | New compounds | |
SE0102055D0 (sv) | New Compounds | |
SE0303480D0 (sv) | Benzofuranes | |
WO2006029210A3 (en) | Acyclic 1,3-diamines and uses therefor | |
MX2008012093A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos. | |
ATE399164T1 (de) | Antagonisten des opioidrezeptors | |
NO20081736L (no) | Antitumormidler | |
EA015500B9 (ru) | Новые антагонисты мсн рецепторов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |